Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 15/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561081 | 0.94 | FAAH (0.56) | FAAHCNR2NPC1RAB9A | |
| SCHEMBL2007027 | 0.79 | FAAH (0.51) | FAAHCNR2NPC1RAB9APOLB | |
| SCHEMBL532234 | 0.78 | FAAH (0.55) | FAAHNPC1RAB9ADPP4 | |
| SCHEMBL13003027 | 0.78 | NPC1 (0.60) | FAAHNPC1RAB9A | |
| SCHEMBL3763277 | 0.74 | FAAH (0.73) | FAAHNPC1RAB9A | |
| SCHEMBL12244696 | 0.74 | HRH3 (0.60) | FAAHCNR2NPC1RAB9ADPP4 | |
| SCHEMBL8170423 | 0.73 | FAAH (0.61) | FAAHCNR2NPC1RAB9AMAPT | |
| SCHEMBL3761142 | 0.72 | CNR2 (0.59) | FAAHCNR2NPC1RAB9APOLB | |
| SCHEMBL12244801 | 0.72 | HRH3 (0.57) | FAAHCNR2NPC1RAB9ADPP4 | |
| SCHEMBL3004397 | 0.71 | FAAH (0.91) | FAAHPOLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | FAAH 64/4885CNR2 2/4885NPC1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.